The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Kristian Wachtell

Copenhagen University Hospital in Glostrup

Glostrup

Denmark

[email]@wachtell.net

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Copenhagen University Hospital in Glostrup, Glostrup, Denmark. 2002 - 2010
  • Department of Cardiology, Rigshospitalet, Denmark. 2010
  • Department of Cardiology B2142, The Heart Center, Rigshospitalet, 9 Blegdamsvej, Denmark. 2006 - 2008
  • Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark. 2002 - 2007

References

  1. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Wachtell, K., Palmieri, V., Gerdts, E., Bella, J.N., Aurigemma, G.P., Papademetriou, V., Dahlöf, B., Aalto, T., Ibsen, H., Rokkedal, J.E., Devereux, R.B. Am. J. Cardiol. (2010) [Pubmed]
  2. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Wachtell, K., Gerdts, E., Palmieri, V., Olsen, M.H., Nieminen, M.S., Papademetriou, V., Boman, K., Dahlöf, B., Aurigemma, G.P., Rokkedal, J.E., Devereux, R.B. J. Hypertens. (2010) [Pubmed]
  3. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Wachtell, K., Gerdts, E., Aurigemma, G.P., Boman, K., Dahlöf, B., Nieminen, M.S., Olsen, M.H., Okin, P.M., Palmieri, V., Rokkedal, J.E., Devereux, R.B. Blood Press. (2010) [Pubmed]
  4. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Wachtell, K., Devereux, R.B., Lyle, P.A., Okin, P.M., Gerdts, E. Ther. Adv. Cardiovasc. Dis (2008) [Pubmed]
  5. Is it time to change the definition of normal urinary albumin excretion?. Wachtell, K., Olsen, M.H. Nature Clinical Practice. Nephrology (2008) [Pubmed]
  6. The effect of angiotensin receptor blockers for preventing atrial fibrillation. Wachtell, K., Devereux, R.B., Lyle, A.P. Curr. Hypertens. Rep. (2007) [Pubmed]
  7. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Wachtell, K., Okin, P.M., Olsen, M.H., Dahlöf, B., Devereux, R.B., Ibsen, H., Kjeldsen, S.E., Lindholm, L.H., Nieminen, M.S., Thygesen, K. Circulation (2007) [Pubmed]
  8. Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Wachtell, K., Devereux, R.B., Lyle, P.A. Curr. Cardiol. Rep (2006) [Pubmed]
  9. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Wachtell, K., Hornestam, B., Lehto, M., Slotwiner, D.J., Gerdts, E., Olsen, M.H., Aurup, P., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S.E., Lindholm, L.H., Nieminen, M.S., Rokkedal, J., Devereux, R.B. J. Am. Coll. Cardiol. (2005) [Pubmed]
  10. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Wachtell, K., Lehto, M., Gerdts, E., Olsen, M.H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S.E., Lindholm, L.H., Nieminen, M.S., Devereux, R.B. J. Am. Coll. Cardiol. (2005) [Pubmed]
  11. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Wachtell, K., Papademetriou, V., Smith, G., Gerdts, E., Dahlöf, B., Engblom, E., Aurigemma, G.P., Bella, J.N., Ibsen, H., Rokkedal, J., Devereux, R.B. Am. Heart J. (2004) [Pubmed]
  12. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Wachtell, K., Ibsen, H., Olsen, M.H., Borch-Johnsen, K., Lindholm, L.H., Mogensen, C.E., Dahlöf, B., Devereux, R.B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S.E., Kristianson, K., Lederballe-Pedersen, O., Nieminen, M.S., Okin, P.M., Omvik, P., Oparil, S., Wedel, H., Snapinn, S.M., Aurup, P. Ann. Intern. Med. (2003) [Pubmed]
  13. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Wachtell, K., Palmieri, V., Olsen, M.H., Bella, J.N., Aalto, T., Dahlöf, B., Gerdts, E., Wright, J.T., Papademetriou, V., Mogensen, C.E., Borch-Johnsen, K., Ibsen, H., Devereux, R.B. Am. Heart J. (2002) [Pubmed]
  14. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Wachtell, K., Olsen, M.H., Dahlöf, B., Devereux, R.B., Kjeldsen, S.E., Nieminen, M.S., Okin, P.M., Papademetriou, V., Mogensen, C.E., Borch-Johnsen, K., Ibsen, H. J. Hypertens. (2002) [Pubmed]
  15. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Wachtell, K., Bella, J.N., Rokkedal, J., Palmieri, V., Papademetriou, V., Dahlöf, B., Aalto, T., Gerdts, E., Devereux, R.B. Circulation (2002) [Pubmed]
  16. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Wachtell, K., Palmieri, V., Olsen, M.H., Gerdts, E., Papademetriou, V., Nieminen, M.S., Smith, G., Dahlöf, B., Aurigemma, G.P., Devereux, R.B. Circulation (2002) [Pubmed]
  17. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Wachtell, K., Dahlöf, B., Rokkedal, J., Papademetriou, V., Nieminen, M.S., Smith, G., Gerdts, E., Boman, K., Bella, J.N., Devereux, R.B. Am. Heart J. (2002) [Pubmed]
 
WikiGenes - Universities